RNA Pioneer Phillip Zamore Joins TransCode Therapeutics' Scientific Advisory Board
TL;DR
Dr. Zamore's appointment enhances TransCode's RNA-targeted cancer therapy programs, giving a strategic advantage in cutting-edge treatment.
Dr. Zamore, a pioneer in RNA biology, joins TransCode's Scientific Advisory Board, advancing innovative RNA therapeutics for metastatic tumors.
Dr. Zamore's work at TransCode offers hope for improved cancer treatments, potentially leading to better outcomes for patients battling metastatic disease.
Joining TransCode, Dr. Zamore brings groundbreaking expertise in RNA research, expanding possibilities for cutting-edge cancer therapies.
Found this article helpful?
Share it with your network and spread the knowledge!
TransCode Therapeutics has appointed Dr. Phillip D. Zamore to its Scientific Advisory Board, a strategic move that could significantly enhance the company's RNA-targeted cancer therapy research. Dr. Zamore, a renowned expert in RNA interference (RNAi) and co-founder of Alnylam Pharmaceuticals, brings extensive expertise in RNA biology and gene silencing mechanisms.
As Chair of the RNA Therapeutics Institute at UMass Chan Medical School, Zamore's election to the National Academy of Sciences underscores his significant contributions to the field. His addition to TransCode's advisory board signals a potential acceleration in the company's innovative approach to treating metastatic cancers.
TransCode's lead therapeutic candidate, TTX-MC138, focuses on treating metastatic tumors that overexpress microRNA-10b, a unique biomarker of metastasis. With Zamore's expertise, the company may be better positioned to develop advanced RNA therapeutic strategies that could potentially transform cancer treatment approaches.
The appointment highlights the ongoing evolution of RNA-based therapeutics and their increasing importance in targeting complex genetic mechanisms underlying diseases like cancer. Zamore's involvement could provide critical insights into improving RNA delivery technologies and identifying novel genetic targets for treatment.
Curated from InvestorBrandNetwork (IBN)
